Humanized TP53 R248Q/− mutated murine CRC organoids synergistically responded to a Palbociclib-Ganetespib combination compared to single drug treatments, including a reduction of organoid size and numbers (Fig. 7A). The gene discussed is TP53; the disease is colorectal carcinoma.